- Home
- ACIU vs III Comparison
ACIU vs III Comparison
Compare ACIU & III Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACIU | III |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | Switzerland | United States |
| Employees | N/A | 1500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.3M | 250.9M |
| IPO Year | 2015 | 2006 |
Fundamental Metrics
Financial Performance| Metric | ACIU | III |
|---|---|---|
| Price | $3.02 | $4.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $10.00 | $5.50 |
| AVG Volume (30 Days) | ★ 330.1K | 292.1K |
| Earning Date | 01-01-0001 | 06-09-2026 |
| Dividend Yield | N/A | ★ 4.49% |
| EPS Growth | N/A | ★ 216.67 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $192,745,000.00 |
| Revenue This Year | N/A | $4.62 |
| Revenue Next Year | $495.67 | $5.22 |
| P/E Ratio | ★ N/A | $21.11 |
| Revenue Growth | N/A | ★ 4.51 |
| 52 Week Low | $1.43 | $3.38 |
| 52 Week High | $4.00 | $6.45 |
Technical Indicators
Market Signals| Indicator | ACIU | III |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 28.17 |
| Support Level | $2.57 | N/A |
| Resistance Level | $3.92 | $5.03 |
| Average True Range (ATR) | 0.21 | 0.19 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 72.56 | 13.46 |
Price Performance
Historical ComparisonAbout ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About III Information Services Group Inc.
Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.